Short-term administration of the GLP-1 analog liraglutide decreases circulating leptin and increases GIP levels and these changes are associated with alterations in CNS responses to food cues: A randomized, placebo-controlled, crossover study

Metabolism: Clinical and Experimental

Volumn 65, Issue 7, 2016, Pages 945-953

  Farr, Olivia M ^a   Tsoukas, Michael A ^a   Triantafyllou, Georgios ^a   Dincer, Fadime ^a   Filippaios, Andreas ^a   Ko, Byung Joon ^a   Mantzoros, Christos S ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Diabetes; fMRI; GLP 1; Leptin; Liraglutide; Obesity

Indexed keywords

ADIPONECTIN; AMYLIN; CHOLESTEROL; FATTY ACID; FIBROBLAST GROWTH FACTOR 21; GASTRIC INHIBITORY POLYPEPTIDE; GHRELIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN; IRISIN; LEPTIN; LIRAGLUTIDE; LOW DENSITY LIPOPROTEIN; PANCREAS POLYPEPTIDE; PEPTIDE YY; PLACEBO; THYROID HORMONE; THYROTROPIN; TRIACYLGLYCEROL; ANTIDIABETIC AGENT;

ADULT; ARTICLE; ASSOCIATION; ATTENTION; BODY WEIGHT; CENTRAL NERVOUS SYSTEM FUNCTION; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CROSSOVER PROCEDURE; DORSOLATERAL PREFRONTAL CORTEX; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ENERGY BALANCE; FATTY ACID BLOOD LEVEL; FEMALE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; FUNCTIONAL NEUROIMAGING; GLUCOSE BLOOD LEVEL; HORMONE BLOOD LEVEL; HUMAN; INSULA; LIPOPROTEIN BLOOD LEVEL; MALE; MESENCEPHALON; MOTOR CORTEX; NON INSULIN DEPENDENT DIABETES MELLITUS; PARIETAL CORTEX; PRECUNEUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REWARD; SATIETY; SHORT COURSE THERAPY; THALAMUS; THYROID HORMONE BLOOD LEVEL; THYROTROPIN BLOOD LEVEL; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; VISUAL ANALOG SCALE; WEIGHT CHANGE; BLOOD; BRAIN; DIAGNOSTIC IMAGING; IMAGE PROCESSING; METABOLISM; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSIOLOGY;

ATTENTION; BRAIN; CROSS-OVER STUDIES; CUES; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; FUNCTIONAL NEUROIMAGING; GASTRIC INHIBITORY POLYPEPTIDE; GHRELIN; HUMANS; HYPOGLYCEMIC AGENTS; IMAGE PROCESSING, COMPUTER-ASSISTED; LEPTIN; LIRAGLUTIDE; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PEPTIDE YY; REWARD;

EID: 84963986318     PISSN: 00260495     EISSN: 15328600     Source Type: Journal    
DOI: 10.1016/j.metabol.2016.03.009     Document Type: Article

References (77)

1. G. Hotamisligil Inflammation and metabolic disorders Nature 444 2006
2. K.N. Aronis, M.A. Tsoukas, and C.S. Mantzoros Potential cardioprotective action of glp-1: from bench to bedside Metabolism 63 8 2014 979 988
3. T. Vilsboll, M. Zdravkovic, T. Le-Thi, T. Krarup, O. Schmitz, J.P. Courreges, and et al. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes Diabetes Care 30 6 2007 1608 1610
4. D.J. Drucker The biology of incretin hormones Cell Metab 3 3 2006 153 165
5. K. Hunter, and C. Holscher Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis BMC Neurosci 13 2012 33
6. S. Sisley, R. Gutierrez-Aguilar, M. Scott, D.A. D'Alessio, D.A. Sandoval, and R.J. Seeley Neuronal glp1r mediates liraglutide's anorectic but not glucose-lowering effect J Clin Invest 124 6 2014 2456 2463
7. L. van Bloemendaal, R.J. IJzerman, J.S. Ten Kulve, F. Barkhof, R.J. Konrad, M.L. Drent, and et al. Glp-1 receptor activation modulates appetite- and reward-related brain areas in humans Diabetes 63 12 2014 4186 4196
8. O.M. Farr, C. Fiorenza, P. Papageorgiou, M. Brinkoetter, F. Ziemke, B.B. Koo, and et al. Leptin therapy alters appetite and neural responses to food stimuli in brain areas of leptin-sensitive subjects without altering brain structure J Clin Endocrinol Metab 99 12 2014 E2529 E2538
9. S.J. Konturek, J. Pepera, K. Zabielski, P.C. Konturek, T. Pawlik, A. Szlachcic, and et al. Brain-gut axis in pancreatic secretion and appetite control J Physiol Pharmacol 54 3 2003 293 317
10. S.J. Konturek, R. Zabielski, J.W. Konturek, and J. Czarnecki Neuroendocrinology of the pancreas; role of brain-gut axis in pancreatic secretion Eur J Pharmacol 481 1 2003 1 14
11. J. Orr, and B. Davy Dietary influences on peripheral hormones regulating energy intake: potential applications for weight management J Am Diet Assoc 105 7 2005 1115 1124
12. O.M. Farr, M. Sofopoulos, M.A. Tsoukas, F. Dincer, B. Thakkar, A. Sahin-Efe, and et al. Glp-1 receptors exist in the parietal cortex, hypothalamus and medulla of human brains and the glp-1 analogue liraglutide alters brain activity related to highly desirable food cues in individuals with diabetes: A crossover, randomised, placebo-controlled trial Diabetologia 2016 [Epub ahead of print]
13. C.K. Welt, J.L. Chan, J. Bullen, R. Murphy, P. Smith, A.M. DePaoli, and et al. Recombinant human leptin in women with hypothalamic amenorrhea N Engl J Med 351 10 2004 987 997
14. O.M. Farr, B.J. Ko, K.E. Joung, L. Zaichenko, N. Usher, M. Tsoukas, and et al. Posttraumatic stress disorder, alone or additively with early life adversity, is associated with obesity and cardiometabolic risk Nutr Metab Cardiovasc Dis 25 5 2015 479 488
15. J. van Can, B. Sloth, C.B. Jensen, A. Flint, E.E. Blaak, and W.H. Saris Effects of the once-daily glp-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults Int J Obes (Lond) 38 6 2014 784 793
16. H. Harder, L. Nielsen, D.T. Tu, and A. Astrup The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes Diabetes Care 27 8 2004 1915 1921
17. M. Horowitz, A. Flint, K.L. Jones, C. Hindsberger, M.F. Rasmussen, C. Kapitza, and et al. Effect of the once-daily human glp-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes Diabetes Res Clin Pract 97 2 2012 258 266
18. D. Beiroa, M. Imbernon, R. Gallego, A. Senra, D. Herranz, F. Villarroya, and et al. Glp-1 agonism stimulates brown adipose tissue thermogenesis and browning through hypothalamic ampk Diabetes 63 10 2014 3346 3358
19. J.L. Chan, K. Heist, A.M. DePaoli, J.D. Veldhuis, and C.S. Mantzoros The role of falling leptin levels in the neuroendocrine and metabolic adaptation to short-term starvation in healthy men J Clin Invest 111 9 2003 1409 1421
20. P.J. Larsen, C. Fledelius, L.B. Knudsen, and M. Tang-Christensen Systemic administration of the long-acting glp-1 derivative nn2211 induces lasting and reversible weight loss in both normal and obese rats Diabetes 50 11 2001 2530 2539
21. C. Clemmensen, J. Chabenne, B. Finan, L. Sullivan, K. Fischer, D. Kuchler, and et al. Glp-1/glucagon coagonism restores leptin responsiveness in obese mice chronically maintained on an obesogenic diet Diabetes 63 4 2014 1422 1427
22. K.A. Al-Barazanji, J.R. Arch, R.E. Buckingham, and M. Tadayyon Central exendin-4 infusion reduces body weight without altering plasma leptin in (fa/fa) zucker rats Obes Res 8 4 2000 317 323
23. A. Aziz, G.H. Anderson, A. Giacca, and F. Cho Hyperglycemia after protein ingestion concurrent with injection of a glp-1 receptor agonist in rats: A possible role for dietary peptides Am J Physiol Regul Integr Comp Physiol 289 3 2005 R688 R694
24. M. He, H. Su, W. Gao, S.M. Johansson, Q. Liu, X. Wu, and et al. Reversal of obesity and insulin resistance by a non-peptidic glucagon-like peptide-1 receptor agonist in diet-induced obese mice PLoS One 5 12 2010 e14205
25. E.W. Iepsen, J. Lundgren, C. Dirksen, J.E. Jensen, O. Pedersen, T. Hansen, and et al. Treatment with a glp-1 receptor agonist diminishes the decrease in free plasma leptin during maintenance of weight loss Int J Obes (Lond) 39 5 2015 834 841
26. V. Patel, A. Joharapurkar, N. Dhanesha, S. Kshirsagar, K. Patel, R. Bahekar, and et al. Co-agonist of glucagon and glp-1 reduces cholesterol and improves insulin sensitivity independent of its effect on appetite and body weight in diet-induced obese c57 mice Can J Physiol Pharmacol 91 12 2013 1009 1015
27. V. Patel, A. Joharapurkar, T. Gandhi, K. Patel, N. Dhanesha, S. Kshirsagar, and et al. Omeprazole improves the anti-obesity and antidiabetic effects of exendin-4 in db/db mice (- 4 db/db)∗ J Diabetes 5 2 2013 163 171
28. A. Pocai, P.E. Carrington, J.R. Adams, M. Wright, G. Eiermann, L. Zhu, and et al. Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice Diabetes 58 10 2009 2258 2266
29. H. Su, M. He, H. Li, Q. Liu, J. Wang, Y. Wang, and et al. Boc5, a non-peptidic glucagon-like peptide-1 receptor agonist, invokes sustained glycemic control and weight loss in diabetic mice PLoS One 3 8 2008 e2892
30. M. Claret, H. Corominola, I. Canals, B. Nadal, A. Chavanieu, B. Pfeiffer, and et al. S 23521 decreases food intake and body weight gain in diet-induced obese rats Obes Res 12 10 2004 1596 1603
31. R. Liu, D. Ma, Y. Li, R. Hu, Y. Peng, and Q. Wang The anorexic effect of ex4/fc through glp-1 receptor activation in high-fat diet fed mice Acta Biochim Biophys Sin (Shanghai) 46 8 2014 675 681
32. L.K. Malendowicz, C. Macchi, G.G. Nussdorfer, K.W. Nowak, A. Zyterska, and A. Ziolkowska Effects of prolonged exendin-4 administration on entero-insular axis of normal and streptozotocin-induced diabetic rats Int J Mol Med 11 6 2003 763 766
33. D. Perez-Tilve, L. Gonzalez-Matias, M. Alvarez-Crespo, R. Leiras, S. Tovar, C. Dieguez, and et al. Exendin-4 potently decreases ghrelin levels in fasting rats Diabetes 56 1 2007 143 151
34. A.E. Hogan, G. Gaoatswe, L. Lynch, M.A. Corrigan, C. Woods, J. O'Connell, and et al. Glucagon-like peptide 1 analogue therapy directly modulates innate immune-mediated inflammation in individuals with type 2 diabetes mellitus Diabetologia 57 4 2014 781 784
35. C. Daousi, J.H. Pinkney, J. Cleator, J.P. Wilding, and L.R. Ranganath Acute peripheral administration of synthetic human glp-1 (7-36 amide) decreases circulating il-6 in obese patients with type 2 diabetes mellitus: A potential role for glp-1 in modulation of the diabetic pro-inflammatory state? Regul Pept 183 2013 54 61
36. G. Diaz-Soto, D.A. de Luis, R. Conde-Vicente, O. Izaola-Jauregui, C. Ramos, and E. Romero Beneficial effects of liraglutide on adipocytokines, insulin sensitivity parameters and cardiovascular risk biomarkers in patients with type 2 diabetes: A prospective study Diabetes Res Clin Pract 104 1 2014 92 96
37. C. Drewes, M.A. Nauck, R. Horn, J. Holst, W. Schmiegel, and G. Brabant A liquid mixed meal or exogenous glucagon-like peptide 1 (glp-1) do not alter plasma leptin concentrations in healthy volunteers Acta Diabetol 34 3 1997 230 234
38. J.P. Gutzwiller, B. Goke, J. Drewe, P. Hildebrand, S. Ketterer, D. Handschin, and et al. Glucagon-like peptide-1: A potent regulator of food intake in humans Gut 44 1 1999 81 86
39. A. Jeibmann, S. Zahedi, M. Simoni, E. Nieschlag, and M.M. Byrne Glucagon-like peptide-1 reduces the pulsatile component of testosterone secretion in healthy males Eur J Clin Invest 35 9 2005 565 572
40. A. Shalev, S. Vosmeer, and U. Keller Absence of short-term effects of glucagon-like peptide-1 and of hyperglycemia on plasma leptin levels in man Metabolism 46 7 1997 723 725
41. N. Wada, S. Hirako, F. Takenoya, H. Kageyama, M. Okabe, and S. Shioda Leptin and its receptors J Chem Neuroanat 61-62 2014 191 199
42. O.M. Farr, M.A. Tsoukas, and C.S. Mantzoros Leptin and the brain: influences on brain development, cognitive functioning and psychiatric disorders Metabolism 64 1 2015 114 130
43. D.S. Le, N. Pannacciulli, K. Chen, A. Del Parigi, A.D. Salbe, E.M. Reiman, and et al. Less activation of the left dorsolateral prefrontal cortex in response to a meal: A feature of obesity Am J Clin Nutr 84 4 2006 725 731
44. D.S. Le, N. Pannacciulli, K. Chen, A.D. Salbe, A. Del Parigi, J.O. Hill, and et al. Less activation in the left dorsolateral prefrontal cortex in the reanalysis of the response to a meal in obese than in lean women and its association with successful weight loss Am J Clin Nutr 86 3 2007 573 579
45. K.M. Rapuano, J.F. Huckins, J.D. Sargent, T.F. Heatherton, and W.M. Kelley Individual differences in reward and somatosensory-motor brain regions correlate with adiposity in adolescents Cereb Cortex 2015 [Epub ahead of print]
46. K.C. Berridge Food reward: brain substrates of wanting and liking Neurosci Biobehav Rev 20 1 1996 1 25
47. M. Rosen, C. Stern, K. Devaney, and D. Somers Functional mri reveals a cognitive control subnetwork supporting long-term memory-guided visual attention J Vis 15 12 2015 1247
48. C. Neale, P. Johnston, M. Hughes, and A. Scholey Functional activation during the rapid visual information processing task in a middle aged cohort: An fmri study PLoS One 10 10 2015 e0138994
49. L. Mason, N.J. Trujillo-Barreto, R.P. Bentall, and W. El-Deredy Attentional bias predicts increased reward salience and risk taking in bipolar disorder Biol Psychiatry 2015
50. A.H. Hosseini, and C.B. Holroyd Reward feedback stimuli elicit high-beta eeg oscillations in human dorsolateral prefrontal cortex Sci Rep 5 2015 13021
51. S. Carnell, C. Gibson, L. Benson, C.N. Ochner, and A. Geliebter Neuroimaging and obesity: current knowledge and future directions Obes Rev 13 1 2012 43 56
52. K. Irlbacher, A. Kraft, S. Kehrer, and S.A. Brandt Mechanisms and neuronal networks involved in reactive and proactive cognitive control of interference in working memory Neurosci Biobehav Rev 46 Pt 1 2014 58 70
53. A. Bari, and T.W. Robbins Inhibition and impulsivity: behavioral and neural basis of response control Prog Neurobiol 108 2013 44 79
54. V. Prevosto, and M.A. Sommer Cognitive control of movement via the cerebellar-recipient thalamus Front Syst Neurosci 7 2013 56
55. M. Corbetta, J.M. Kincade, and G.L. Shulman Neural systems for visual orienting and their relationships to spatial working memory J Cogn Neurosci 14 3 2002 508 523
56. M. Corbetta, and G.L. Shulman Control of goal-directed and stimulus-driven attention in the brain Nat Rev Neurosci 3 3 2002 201 215
57. K.L. McFadden, M.A. Cornier, E.L. Melanson, J.L. Bechtell, and J.R. Tregellas Effects of exercise on resting-state default mode and salience network activity in overweight/obese adults Neuroreport 24 15 2013 866 871
58. R. Polania, M. Moisa, A. Opitz, M. Grueschow, and C.C. Ruff The precision of value-based choices depends causally on fronto-parietal phase coupling Nat Commun 6 2015 8090
59. C.F. Deacon, and B. Ahren Physiology of incretins in health and disease Rev Diabet Stud 8 3 2011 293 306
60. C.F. Deacon What do we know about the secretion and degradation of incretin hormones? Regul Pept 128 2 2005 117 124
61. A. El-Ouaghlidi, E. Rehring, J.J. Holst, A. Schweizer, J. Foley, D. Holmes, and et al. The dipeptidyl peptidase 4 inhibitor vildagliptin does not accentuate glibenclamide-induced hypoglycemia but reduces glucose-induced glucagon-like peptide 1 and gastric inhibitory polypeptide secretion J Clin Endocrinol Metab 92 11 2007 4165 4171
62. H.J. Woerle, L. Carneiro, A. Derani, B. Goke, and J. Schirra The role of endogenous incretin secretion as amplifier of glucose-stimulated insulin secretion in healthy subjects and patients with type 2 diabetes Diabetes 61 9 2012 2349 2358
63. N. Mentis, I. Vardarli, L.D. Kothe, J.J. Holst, C.F. Deacon, M. Theodorakis, and et al. Gip does not potentiate the antidiabetic effects of glp-1 in hyperglycemic patients with type 2 diabetes Diabetes 60 4 2011 1270 1276
64. A. Lund, T. Vilsboll, J.I. Bagger, J.J. Holst, and F.K. Knop The separate and combined impact of the intestinal hormones, gip, glp-1, and glp-2, on glucagon secretion in type 2 diabetes Am J Physiol Endocrinol Metab 300 6 2011 E1038 E1046
65. M. Salehi, B. Aulinger, R.L. Prigeon, and D.A. D'Alessio Effect of endogenous glp-1 on insulin secretion in type 2 diabetes Diabetes 59 6 2010 1330 1337
66. J.J. Meier, G. Kemmeries, J.J. Holst, and M.A. Nauck Erythromycin antagonizes the deceleration of gastric emptying by glucagon-like peptide 1 and unmasks its insulinotropic effect in healthy subjects Diabetes 54 7 2005 2212 2218
67. U. Kielgast, J.J. Holst, and S. Madsbad Antidiabetic actions of endogenous and exogenous glp-1 in type 1 diabetic patients with and without residual beta-cell function Diabetes 60 5 2011 1599 1607
68. A. Flint, A. Raben, A.K. Ersboll, J.J. Holst, and A. Astrup The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity Int J Obes Relat Metab Disord 25 6 2001 781 792
69. M. Toft-Nielsen, S. Madsbad, and J.J. Holst Exaggerated secretion of glucagon-like peptide-1 (glp-1) could cause reactive hypoglycaemia Diabetologia 41 10 1998 1180 1186
70. E.T. Rolls Taste, olfactory, and food reward value processing in the brain Prog Neurobiol 127-128 2015 64 90
71. E.T. Rolls Functions of the anterior insula in taste, autonomic, and related functions Brain Cogn 2015
72. D. Val-Laillet, E. Aarts, B. Weber, M. Ferrari, V. Quaresima, L.E. Stoeckel, and et al. Neuroimaging and neuromodulation approaches to study eating behavior and prevent and treat eating disorders and obesity Neuroimage Clin 8 2015 1 31
73. L. Wang, H. Yu, J. Hu, J. Theeuwes, X. Gong, Y. Xiang, and et al. Reward breaks through center-surround inhibition via anterior insula Hum Brain Mapp 2015
74. M.A. Wijngaarden, I.M. Veer, S.A. Rombouts, M.A. van Buchem, K. Willems van Dijk, H. Pijl, and et al. Obesity is marked by distinct functional connectivity in brain networks involved in food reward and salience Behav Brain Res 287 2015 127 134
75. J. Nyberg, M.F. Anderson, B. Meister, A.M. Alborn, A.K. Strom, A. Brederlau, and et al. Glucose-dependent insulinotropic polypeptide is expressed in adult hippocampus and induces progenitor cell proliferation J Neurosci 25 7 2005 1816 1825
76. J. Nyberg, C. Jacobsson, M.F. Anderson, and P.S. Eriksson Immunohistochemical distribution of glucose-dependent insulinotropic polypeptide in the adult rat brain J Neurosci Res 85 10 2007 2099 2119
77. C.K. Kramer, B. Zinman, H. Choi, P.W. Connelly, and R. Retnakaran The impact of chronic liraglutide therapy on glucagon secretion in type 2 diabetes: insight from the libra trial J Clin Endocrinol Metab 100 10 2015 3702 3709